Article Tools
Add to My Bookmarks
Adds Article to your Entrepreneur Assist Bookmark page.
PITTSBORO -- Biolex Therapeutics, which is developing treatments
for hepatitis C, withdrew plans to go public because of unfavorable
market conditions and because it had found financing elsewhere. Biolex
never said how much money it planned to raise in the stock offering.
COPYRIGHT 2008 Business North
Carolina Reproduced with permission of the copyright holder. Further reproduction or distribution is prohibited without permission.
Copyright 2008 Gale, Cengage Learning. All rights
reserved. Gale Group is a Thomson Corporation Company.
NOTE: All illustrations and photos have been removed from this article.
Browse by Journal Name: